City & Corporate: FD wins major pharma work

Hikma awards FD retained account after competitive four-way pitch.

FD has taken one of the largest healthcare firms listed on the London Stock Exchange from City rival Brunswick.

Hikma Pharmaceuticals, the fourth-largest Londonlisted firm in the sector, with a market cap of £1.3bn, has handed its retained financial and investor relations account to FD following a competitive pitch.

The FTSE 250 firm is based in Jordan and is listed on the NASDAQ Dubai exchange.

Previous incumbent Brunswick is understood to have repitched for the brief, alongside M:Communications and Capital MS&L - all agencies with a significant footprint in the Middle East.

Hikma operates principally in the Middle East and North Africa (MENA), and has built market-leading positions in these emerging markets, helping it become one of the few major international pharmaceutical firms posting strong growth in recent times.

Ben Atwell, an MD in the agency's life science team in London, said: 'Hikma is well established as one of the market leaders in its key MENA markets, as well as having a growing presence in the US and other parts of the world.'

Industry analysts suggest as much as 70 per cent of growth in the sector over the next five years will be driven by emerging markets.

Hikma is targeting double-digit annual growth and has already seen its UK share price rise by about 65 per cent in the past year.

FD will support this growth by managing its financial and investor comms both globally and regionally.

Atwell and fellow life sciences MDs Julia Phillips and Jonathan Birt will lead the account from the UK, supported by John Hobday, head of FD's UEA office, and Tala Abu Taha from FD's affiliate in Jordan, VARCC Communications.

FD's life sciences division has concentrated on growth internationally in recent times, expanding out of its traditional UK client list to pick up clients in further emerging markets such as Connexios in India.

Emerging markets are increasingly becoming a focus for multinational pharma giants. GlaxoSmithKline has bought firms in Argentina and South Korea, plus a stake in South Africa's Aspen Pharmacare in the past year, while Sanofi-Aventis has made acquisitions in Central and Eastern European, Brazil and Mexico.

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus

Latest Articles

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

Max Clifford trial jury to reconvene tomorrow after majority verdicts direction

The jury in the trial of celebrity publicist Max Clifford on 11 charges of indecent assault has been sent home for the day after being told by the judge earlier this afternoon that he will now accept majority verdicts.

Labour "fooling themselves" over plans to combat attacks on Miliband

Labour "fooling themselves" over plans to combat attacks on Miliband

Conservative-leaning public affairs experts have questioned the value of Labour's adoption of US-style campaigning tactics in the wake of the opposition hiring election strategist David Axelrod.

PLMR appoints Professor Tim Morris as non-executive director

The vet who helped establish the British Horseracing Authority's anti-doping and animal welfare programme has joined PLMR as a non-executive director.